DMARDs are defined as medications that reduce or halt the disease progression by rapid and sustained suppression of inflammation, but incapable of curing the disease. 24 They can be categorized as, conventional DMARDs (cDMARDs) and newly introduced biologic DMARDs (biologics). Among cDMARDs, the most efficacious is methotrexate (MTX), 25 due to its highest retention rates. Nevertheless, combination of MTX with one or more of the other cDMARDs or combination of MTX with a biologic has shown improved response in clinical trials than monotherapies of DMARDs. 26, 27 Biologics Biologics are drugs produced from living organisms or contain components of living organisms (blood, blood components, cells, allergens, genes, tissues and recombinant proteins), 28 that have been formulated to specifically block or alter the function of cytokines.
Anti-TNFα Biologics
Placing TNFα at the center of RA pathogenesis has led RA to be the first disease for which anti-TNF biologics were used. 28 In clinical settings, anti-TNF biologics have been efficacious in 60%-70% of RA patients whose disease activity was persistent despite cDMARD treatment. 29 Apart from improving the clinical symptoms of RA, TNF antagonists provide protection against joint destruction, disability and improve quality of life, 30 thus addressing most of the aims of RA pharmacotherapy.
Currently, three anti-TNF biologics; infliximab, adalimumab and etanercept approved by the Food and Drug Administration (FDA) are utilized in clinical settings. 31 Considering the structures of these drugs (Figure 1 ), infliximab is a chimeric monoclonal antibody that has been genetically engineered by the fusion of two murine TNFbinding epitopes and a Fc portion of a human IgG1. Conversely, adalimumab is a human monoclonal antibody engineered by the combination of two human TNF-binding epitopes and a Fc portion of a human IgG1. Moreover, etanercept is the combination of two naturally occurring soluble human TNF receptors and a Fc portion of a human IgG1.
Furthermore, anti-TNF biologics currently in phase III trials; golimumab, a human monoclonal antibody; 33 and certolizumab pegol, a pegylated fab' fragment of a humanized monoclonal antibody against TNF, 34 are expected to yield similar results as the licensed agents.
Comparison of Effectiveness

Comparison of Clinical Properties
Clinical efficacy of infliximab, adalimumab and etanercept in RA is achieved by their inhibitory properties on; cell activation, cell proliferation, cytokine and chemokine production, inflammation, immune regulation, angiogenesis, and extracellular matrix degradation. 30 Thus, comparison of the clinical properties (Table 1) of anti-TNF biologics is essential to review their effectiveness.
According to Kaymakcalan et al, 35 measurements on binding affinities, using BIAcore and radioimmunoassay methods, reported higher values for sTNFα than mTNFα. on the contrary, Sakorafas et al 36 reported equal affinities for both sTNFα and mTNFα, when kinetic exclusion assay was employed for the measurements, suggesting that the discrepancy in findings may be a consequence of utility of different assays. Moreover, Kaymakcalan et al 35 suggested that, this inconsistency may be due to structural variations ( Figure 2 ). However, it is yet unknown whether the binding affinities of these drugs play an important role in different clinical outcomes. 49 Considering CDC, both infliximab and adalimumab show higher effectiveness, whereas etanercept remain less effective. CDC involves binding of C1q to CH2 domain of IgG1, which initiates the classical complement cascade, thus leading to the eventual formation of membrane attack complex and the resultant cell lysis. 39 Therefore, this discrepancy is believed to be a result of the structure-influenced binding abilities of TNF antagonists to the first complement component, C1q. Accordingly, Arora et al 37 evaluated binding abilities of the three drugs to C1q, using radiolabeled 125 I bound to immobilized C1q (Figure 3 ). Both infliximab and adalimumab showed significant increase in binding along with the increment of C1q concentration, whereas etanercept reported only a slight increase. Moreover, infliximab, adalimumab and etanercept commonly possess the Fc portion of IgG1 (Figure 4 ), whose CH2 domain activates C1q. However, etanercept does not carry the CH1 domain and hinge region of IgG1. 50 This results in conformational hindrance for the proper binding with C1q, thus making its potency low. Nevertheless, CH1 domain being the platform for activation of complement component C3, 51 and hinge region being necessary for the formation of membrane attack complex 52 further explain the reduced CDC activity by etanercept.
As for ADCC, all three drugs showed similar activity, when mTNF-transfected Jurkat T cells were used as target, 38 whereas infliximab and adalimumab were efficacious than etanercept in NS0 cells 39 and CHO cells. 37 Therefore, this discrepancy in etanercept-induced ADCC may be perceived as a consequence of the difference in the species of target cell used. However, structurally all three drugs possess both CH2 and CH3 domains of the Fc region of IgG1 (Figure 4 ), which are crucial for the anti-TNF agents to bind with Fc receptors of NK cells. 53 The NK cells in turn lyse of the target cells by granzyme B and perforin. Consequently, all three drugs should show equal ADCC activity, theoretically. Reverse signaling, a function of TNF agonists for the inhibition of TNFα-producing cells, is mediated by pathways independent of CDC and ADCC ( Figure 5 ). However, upon binding to mTNFα-expressing Jurkat T cells, both infliximab and adalimumab, induce apoptosis and cell cycle G0/G1 arrest, whereas etanercept did not. Watts et al 55 reveal that, this inability of etanercept may be due to the absence of complementary residues to bind with serine residues of mTNFα in order to initiate apoptotic signaling.
As for downregulation of pro-inflammatory cytokines, all three agents have been equally efficacious. According to 37 Ohshima et al, 45 elevated serum IL-6 levels rapidly diminished in each set of patients who received one of the three agents. Nevertheless, etanercept downregulated IFN-γ, GM-CSF and IL-18 42 production in vitro as efficiently as infliximab and adalimumab.
However, infliximab and adalimumab have successfully augmented anti-inflammatory cytokine levels in vitro, whereas etanercept has failed to do so. According to Mitoma et al 43 and Horiuchi et al, 54 all three agents stimulated mTNFα-expressing Jurkat T cells, whereas only infliximab and adalimumab upregulated IL-10 levels in vitro. Nevertheless, elevated serum IL-10 levels in RA patients were further augmented in patients treated with infliximab and adalimumab, whereas no change was observed in patients who were given etanercept. 45 Considering induction of apoptosis, both the monoclonal antibody drugs have been efficacious, whereas the receptor protein has been ineffective. Infliximab and adalimumab have induced apoptosis in cells which express mTNFα such as; lamina propria T-lymphocytes, 48 monocytes, 44 and macrophages. 40 Conversely, they have failed to induce apoptosis in cells which do not express mTNFα, such as lymphocytes. 47 Therefore, induction of apoptosis by infliximab and adalimumab, can be understood as a process dependent on reverse-signaling; a functional property shown only on mTNFα-expressing cells. Thus, the inability of etanercept to induce apoptosis can be understood as a consequence of its ineffectiveness in reverse signaling.
Moreover, improvement of T reg and suppression of T eff by infliximab and adalimumab, is believed to be the result of their influence on the viability T reg and T eff , 56 through mechanisms such as induction of apoptosis. Consequently, etanercept fails to regulate the activity of T cells 55 as it is inefficacious in inducing apoptosis.
Comparison of Patient Response to Treatment
Effectiveness can be further assessed by reviewing the patient response to treatment ( Table 2 ). Regardless when given as monotherapy or in combination with MTX, etanercept has shown augmented response in clinical trials. Nevertheless, it has reported high retention rates as both first-and second-line biologics. Furthermore, literature considers etanercept as the drug of choice for short term therapy. Therefore, collectively, etanercept shows highest rates in overall patient response to therapy. Furthermore, adalimumab can be considered the second most efficacious drug in patients due to highest rate of disease remission and being the drug of choice in long term therapy. Nevertheless, infliximab appears to be the least efficacious in terms of treatment response.
Contraindications
As any other therapeutic method, anti-TNFα biologic therapy too has its contraindications ( Table 3) , which pose a challenge to its therapeutic role. Initially, anti-TNFα biologics were found to reduce the risk of cardiac diseases. 70 However, along with the reported increment of total cholesterol and low-density lipoprotein levels subsequent to anti-TNFα therapy, 71 they are considered to impose risk for MI and congestive heart failure.
Reportedly, TNFα regulates the cytokine mediated cancer immunosurveillance, and Ramanarayanan et al 72 suggest that, blockage of TNFα may revoke anti-tumor immunity and increase the risk of malignancies. Based on more extensive data, current FDA guidelines report an augmented risk of lymphoma in TNF antagonist treated subjects. 73 Moreover, TNF antagonists reportedly destroy macrophagic granulomas containing Mycobacterium tuberculosis 74 via the induction of apoptosis. Therefore, treatment with anti-TNF agents associate high risk of reactivation of TB. Nevertheless, similar mechanisms have been related to the occurrence of other opportunistic infections. 75 In the case of monoclonal antibody drugs, formation of antiinfliximab and anti-adalimumab antibodies 76 cause secondary inefficacy and may cause complete unresponsiveness eventually. Nevertheless, the presence of such antibodies may explain the increased infusion reactions reported with infliximab and adalimumab therapy. 77, 78 Comparison of safety Numerous study groups have attempted to evaluate and compare the safety of infliximab, adalimumab and etanercept (Table 4 ). According to majority of literature, infliximab is the least safe as it is associated with the highest percentage of serious adverse events and infections. However, infliximab reports the least percentage of infusion reactions. Moreover, due to no serious adverse effects being reported at all, literature considers it the safest among the three. Etanercept reports a considerable percentage of infections. However, studies suggest that the increased infusion reactions caused by etanercept do not affect it being the safest, as infusion reactions can be easily dealt by applying cool pack (4 o C), application of topical corticosteroids or by rotating the injection site. 79 As for adalimumab, it reports intermediate safety profile as it is associated with a considerable percentage of adverse effects, but less than that of infliximab and greater than that of etanercept. Moreover, Table 5 further suggests etanercept as the safest and infliximab, the least safe among the three anti TNF agents.
Future Insight
Despite the clinical efficacy of anti-TNF agents, prevalence of potential drawbacks has led research to focus on finding solutions to alleviate negativities. A major drawback is failure to produce response in some patients or producing only a partial response. Nevertheless, molecular remission and the capacity to re-establish immunological tolerance remain elusive till date. Apart from that, systemic toxicity and complications of anti-TNF therapy remain a major challenge. Moreover, there is a notable absence of reliable predictive biomarkers to monitor therapeutic response and toxicity.
Ferrari et al 91 suggest the recruitment of novel strategies; 'Trojan Horse' and 'Guided Missile' drug delivery systems, to actively target and deliver anti-TNFα agents to target sites. Trojan horse drug delivery combines the two theories of polymer conjugation and nanoparticulate drug delivery ( Figure 6 ), whereas guided missile drug delivery addresses formulating drugs as antibody conjugates and bispecific antibodies (Figure 7) . Therefore, formulation of anti-TNF biologics according to these drug delivery concepts is believed to confer improved pharmacokinetic properties, promote in situ action and decrease systemic toxicity.
Nevertheless, researchers believe that gene array analysis will help define individual response to treatment, thus alleviate the heterogenicity in patient response. 93 
Conclusion
In conclusion of the review, it is evident that in terms of effectiveness related to clinical properties, both the monoclonal antibody drugs are efficacious than the receptor protein. However, considering patient response to treatment, both adalimumab and etanercept were superior to infliximab. Considering safety, etanercept is the safest whereas infliximab, is the least safe. Thus, a single drug cannot be named as the most efficacious in terms of both effectiveness and safety. Furthermore, systemic toxicity of anti-TNF agents, induction of heterogenous responses in patients, and above all, inability to achieve disease remission remain as challenges of current anti-TNF therapy.
Therefore, the improvement in structures and pharmacokinetic properties of anti-TNF agents may alleviate the reported drawbacks. Furthermore, it may lead to successful treatment of symptoms, improve safety profiles, and reduce Liposomes can be engineered to bind drugs and degrade only upon reaching the target site, thus it is believed to limit systemic toxicity. Moreover, nanoparticles can be conjugated to polymers that contain encapsulated drugs, thus promote target-specific delivery. Trojan horse drug delivery suggests formulation of drugs as polymeric nanoparticles by combining the above two theories, to achieve combined efficacy. An example is [5] conjugation of RGD to a methotrexate-loaded PLGA-Au nanoparticle32 providing active targeting of αVβ3-expressing endothelial cells. Abbreviations: PLGA, poly(lactic-co-glycolic) acid; RGD, Arg-Gly-Asp peptide; siRNA, small interfering RNA. 91 burden for national healthcare systems. Finally, though proposed future advances in therapy may improve effectiveness and safety, they however seem incapable of providing complete remission. Thus, advancement in research which aims at achieving a cure should be encouraged.
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